At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, and 2 other interventions for Colorectal Adenoma and 3 related conditions. Active but no longer recruiting, targeting 110 participants across 7 sites in 2 countries.
Detailed Summary
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.
Study Details
Timeline
Interventions
Correlative studies
Given SC
Ancillary studies
Given SC